Late Phase Interventional Trials
PAREXEL® Access supports clients with strategies and systems specifically developed for late phase interventional trials. Our experience spans many therapeutic areas and ranges from single-country studies to those carried across multiple national boundaries and continents.
Whether you need to position a product through comparative studies, develop line extensions or extend label claims, we can help expedite Phase IIIb studies from planning to execution.
In an era in which considerable financial resources are at stake, our broad range of late phase services can help sponsors extend their product lifecycle, expand prescribing communities, increase product exposure and maximize return on investment by bridging drug development and commercialization.
PAREXEL has significant experience in the implementation and management of Phase IV trials, including the successful implementation of some of the largest trials of marketed products ever conducted. This operational expertise, coupled with PAREXEL's ability to provide integrated service offerings such as technology solutions that streamline the operations of trials conducted in the Phase IV arena, positions PAREXEL as the CRO of choice.
As a result of this experience, PAREXEL is keenly aware of the challenges faced with managing large studies involving various types of investigative sites. This has allowed us to develop procedures specifically designed to effectively recruit, initiate, and manage these sites, as well as a keen understanding of late phase issues.